
Carlos Jiménez-Cortegana

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/936398/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Role of Leptin in Non-Alcoholic Fatty Liver Disease. Biomedicines, 2021, 9, 762.	3.2	41
2	Obesity as a Risk Factor for Dementia and Alzheimer's Disease: The Role of Leptin. International Journal of Molecular Sciences, 2022, 23, 5202.	4.1	38
3	Myeloid-Derived Suppressor Cells and Radiotherapy. Cancer Immunology Research, 2022, 10, 545-557.	3.4	32
4	Leptin, Both Bad and Good Actor in Cancer. Biomolecules, 2021, 11, 913.	4.0	31
5	Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial. , 2021, 9, e002323.		26
6	Nutritional modulation of leptin expression and leptin action in obesity and obesity-associated complications. Journal of Nutritional Biochemistry, 2021, 89, 108561.	4.2	22
7	Circulating immune biomarkers in peripheral blood correlate with clinical outcomes in advanced breast cancer. Scientific Reports, 2021, 11, 14426.	3.3	17
8	Increased Blood Monocytic Myeloid Derived Suppressor Cells but Low Regulatory T Lymphocytes in Patients with Mild COVID-19. Viral Immunology, 2021, 34, 639-645.	1.3	13
9	Nutrients and Dietary Approaches in Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease: A Narrative Review. Nutrients, 2021, 13, 4150.	4.1	13
10	Circulating regulatory T cells from breast cancer patients in response to neoadjuvant chemotherapy. Translational Cancer Research, 2019, 8, 59-65.	1.0	11
11	Possible Role of Leptin in Atopic Dermatitis: A Literature Review. Biomolecules, 2021, 11, 1642.	4.0	8
12	Lower Survival and Increased Circulating Suppressor Cells in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma with Deficit of Vitamin D Levels Using R-GDP Plus Lenalidomide (R2-GDP): Results from the R2-GDP-GOTEL Trial. Cancers, 2021, 13, 4622.	3.7	6
13	Low Levels of Granulocytic Myeloid-Derived Suppressor Cells May Be a Good Marker of Survival in the Follow-Up of Patients With Severe COVID-19. Frontiers in Immunology, 2021, 12, 801410.	4.8	6
14	Tumor Immune Microenvironment in Lymphoma: Focus on Epigenetics. Cancers, 2022, 14, 1469.	3.7	6
15	Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis. Clinical Cancer Research, 2022, 28, 3658-3668.	7.0	5
16	Pembrolizumab Plus Gemcitabine in the Subset of Triple-Negative Advanced Breast Cancer Patients in the GEICAM/2015-04 (PANGEA-Breast) Study. Cancers, 2021, 13, 5432.	3.7	4
17	MDSCs sneak CSCs out of (immuno)surveillance. Trends in Immunology, 2022, 43, 1-3.	6.8	4
18	Evolution of the myeloid-derived suppressor cells in advanced breast cancer and comparative analysis with a healthy population cohort Journal of Clinical Oncology, 2019, 37, 2543-2543.	1.6	1